logo
logo
AI Products 

Histone Deacetylase Inhibitors Market Growth Trajectory Through 2024-2033

avatar
Vijay Tbrc
Histone Deacetylase Inhibitors Market Growth Trajectory Through 2024-2033

The Histone Deacetylase Inhibitors Global Market Report 2024 by The Business Research Company provides market overview across 60+ geographies in the seven regions - Asia-Pacific, Western Europe, Eastern Europe, North America, South America, the Middle East, and Africa, encompassing 27 major global industries. The report presents a comprehensive analysis over a ten-year historic period (2010-2021) and extends its insights into a ten-year forecast period (2023-2033).

Learn More On The Histone Deacetylase Inhibitors Market:https://www.thebusinessresearchcompany.com/report/histone-deacetylase-inhibitors-global-market-report 

According to The Business Research Company’s Histone Deacetylase Inhibitors Global Market Report 2024, The histone deacetylase inhibitors market size is expected to see strong growth in the next few years. It will grow to $1.64 billion in 2028 at a compound annual growth rate (CAGR) of 8.0%. The growth in the forecast period can be attributed to growing investment in biotechnology, the growing elderly population, favorable regulatory approvals and faster drug approval processes, improved drug delivery systems, and the expansion of therapeutic applications. Major trends in the forecast period include the integration of wearable devices to monitor patient health, innovations in nanotechnology and drug delivery methods, advances in identifying and validating biomarkers, artificial intelligence (AI) and machine learning, and next-generation sequencing.

The increasing incidence of cancer is expected to propel the growth of the histone deacetylase inhibitors market going forward. The rising incidence of cancer is primarily attributed to aging populations, increased exposure to risk factors such as tobacco, diet, and environmental pollutants, and improved diagnostic techniques leading to earlier and more frequent detection. Histone deacetylase inhibitors treat cancer by altering chromatin structure, leading to the activation of tumor suppressor genes and suppression of oncogenes, thereby inducing cell cycle arrest and apoptosis in cancer cells. For instance, in February 2024, according to the World Health Organization, a US-based intergovernmental organization, approximately 35 million new cancer cases were predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the increasing incidence of cancer is driving the growth of the histone deacetylase inhibitors market.

Get A Free Sample Of The Report (Includes Graphs And Tables):https://www.thebusinessresearchcompany.com/sample.aspx?id=17170&type=smp 

The histone deacetylase inhibitors market covered in this report is segmented –

1) By Classification: Class I Histone Deacetylases (HDACs), Class II Histone Deacetylases (HDACs), Class III Histone Deacetylases (HDACs), Other Classifications2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels4) By Application: Oncology, Neurology, Other Applications5) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users

Major companies operating in the histone deacetylase inhibitors market are focusing on developing innovative product formulations, such as oral histone deacetylase (HDAC) inhibitors, to expand treatment options and improve patient convenience and compliance. An oral histone deacetylase (HDAC) inhibitor is a drug taken by mouth that targets HDAC enzymes involved in gene regulation and is potentially used in treating various diseases, including cancer and inflammatory conditions. For instance, in March 2024, Italfarmaco S.p.A., an Italy-based pharmaceutical company, received Food and Drug Administration approval for Duvyzat (givinostat), an oral histone deacetylase (HDAC) inhibitor, for the treatment of Duchenne muscular dystrophy (DMD) in patients aged 6 years and older. Duvyzat is a histone deacetylase (HDAC) inhibitor that mitigates the sequence of events leading to muscle damage, potentially slowing the progression of muscle deterioration associated with DMD. By inhibiting HDAC overactivity, it reduces inflammation and fibrosis while promoting muscle fiber regeneration. The approval is based on the pivotal phase 3 EPIDYS trial, which met its primary endpoint, demonstrating that patients on Duvyzat showed a statistically significant decrease in the time to complete the four-stair climb assessment compared to placebo.

The histone deacetylase inhibitors market report table of contents includes:

1. Executive Summary2. Market Characteristics3. Market Trends And Strategies4. Impact Of COVID-195. Market Size And Growth6. Segmentation7. Regional And Country Analysis...27. Competitive Landscape And Company Profiles28. Key Mergers And Acquisitions29. Future Outlook and Potential Analysis

Contact Us:The Business Research CompanyEurope: +44 207 1930 708Asia: +91 88972 63534Americas: +1 315 623 0293

Email: info@tbrc.info 

Follow Us On:LinkedIn: https://in.linkedin.com/company/the-business-research-company Twitter: https://twitter.com/tbrc_info Facebook: https://www.facebook.com/TheBusinessResearchCompany YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ Blog: https://blog.tbrc.info/ Healthcare Blog: https://healthcareresearchreports.com/ Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model 

collect
0
avatar
Vijay Tbrc
guide
Zupyak is the world’s largest content marketing community, with over 400 000 members and 3 million articles. Explore and get your content discovered.
Read more